The latest findings from the PROTECT phase III trial show sparsentan—a novel treatment for IgA nephropathy—significantly reduces proteinuria, or abnormal protein levels in the urine, compared to standard treatment irbesartan.
from Medical Xpress - latest medical and health news stories https://ift.tt/LJDUCt8
